Heart Vascular Medical Expects H1 2026 Adjusted Net Profit of at Least RMB 70M, Up 104.7% YoY

According to Zhitong Finance, Heart Vascular Medical-B (06609) expects H1 2026 revenues of at least RMB 280 million, up 50.9% year-over-year, and adjusted net profit of at least RMB 70 million, representing growth of at least 104.7%. The company attributed the increase to expanded product recognition among customer bases, broader hospital coverage, and rapid revenue growth across its three core business segments in ischemic stroke, hemorrhagic stroke, and vascular closure.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments